Ovarian Cancer Companion Diagnostic Tests

In 2019, the BRCA1 and BRCA2 Gene Mutation Detection Kit (Reversible Terminator Sequencing) of Xiamen Amoy Diagnostics Co., Ltd. was approved. It is intended for the qualitative detection of point mutations and insertion-deletion mutations using DNA isolated from peripheral whole blood, which contains full and uniform coverage of both BRCA1 and BRCA2 genes, covering all coding exons, exon/intron junctions, some introns, and UTR regions. This kit is used for the Olaparib dosage guidance, filling the gap of approved reagents for the BRCA1/2 gene test in China.

Last: In Vitro Diagnostic Industry in China - Molecular Diagnosis Analyzers and Reagents XVII

Next: In Vitro Diagnostic Industry in China - Molecular Diagnosis Analyzers and Reagents XIX